List of Excipients in Branded Drug JANUVIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	CROSCARMELLOSE SODIUM
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	FERRIC OXIDE RED
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	FERRIC OXIDE YELLOW
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	MAGNESIUM STEARATE

Januvia Excipient Strategy and Commercial Opportunities for Sitagliptin Tablets

Last updated: August 9, 2026

Januvia contains sitagliptin phosphate monohydrate and is marketed as immediate-release film-coated tablets in 25 mg, 50 mg, and 100 mg strengths. Its excipient platform is conventional, which creates opportunities for generic manufacturers, excipient suppliers, contract development organizations, and lifecycle-management programs. The most attractive opportunities are low-risk direct-compression platforms, fixed-dose combinations, moisture-control systems, and cost-optimized film coatings.

Januvia’s commercial exposure remains material because Merck markets sitagliptin globally, including the Januvia brand and the Janumet and Janumet XR combinations. U.S. generic-entry timing is controlled by listed patents, litigation settlements, and regulatory approvals rather than by the excipient composition alone.

What excipients are used in Januvia tablets?

Januvia tablets use a conventional oral solid-dose formulation with a crystalline active ingredient, inorganic diluent, cellulosic binder or filler, superdisintegrant, lubricant, and aqueous or polymeric film coating.

The U.S. prescribing information identifies the following inactive ingredients for Januvia tablets:

Formulation component	Function
Microcrystalline cellulose	Filler, dry binder, compaction aid
Anhydrous dibasic calcium phosphate	Inorganic diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Sodium stearyl fumarate	Lubricant or lubrication-support excipient
Polyvinyl alcohol	Film-forming polymer
Polyethylene glycol	Plasticizer
Talc	Anti-tacking and coating aid
Titanium dioxide	Opacifier and colorant
Iron oxides	Tablet-strength color identification

The exact excipient declaration should be verified against the applicable country label because inactive-ingredient listings can vary by market and manufacturing site. The U.S. label identifies sitagliptin phosphate monohydrate equivalent to 25 mg, 50 mg, or 100 mg of sitagliptin as the active ingredient [1].

Why does Januvia use both microcrystalline cellulose and dibasic calcium phosphate?

The combination balances compactability, tablet strength, disintegration, and manufacturing cost.

Microcrystalline cellulose supports plastic deformation and improves tablet integrity at moderate compression force. Dibasic calcium phosphate provides a dense, free-flowing mineral filler with favorable compaction behavior. The combination is suitable for direct compression or a closely related dry-processing platform.

For generic development, the principal formulation risks are:

• Tablet weight and tensile-strength matching across the three strengths.
• Uniform distribution of the active ingredient at the 25 mg strength.
• Lubricant sensitivity and potential slowing of dissolution.
• Particle-size differences between active and excipient lots.
• Stability under high humidity.
• Color and film-coat matching for commercial identification.

What is the best excipient strategy for generic Januvia?

A generic manufacturer should begin with a direct-compression formulation using compendial, multi-source excipients. The strategy should prioritize bioequivalence, dissolution similarity, process robustness, and supply continuity rather than a novel excipient system.

Recommended formulation platform

A practical starting platform is:

1. Sitagliptin phosphate or an equivalent approved active form.
2. Microcrystalline cellulose as the principal organic filler.
3. Dibasic calcium phosphate as a dense inorganic filler.
4. Croscarmellose sodium as the primary disintegrant.
5. Magnesium stearate or sodium stearyl fumarate as the lubricant system.
6. A conventional polyvinyl alcohol-based film coating.

This platform has several commercial advantages:

• It uses widely available compendial materials.
• It supports multiple tablet strengths.
• It reduces reliance on wet granulation.
• It permits high-throughput compression.
• It simplifies scale-up and technology transfer.
• It creates multiple approved-source options for most excipients.

The 25 mg tablet requires particular attention because the active load is relatively low compared with total tablet mass. Content uniformity can be affected by segregation, electrostatic charging, density differences, and inadequate blending. A pre-blend or ordered-mixing process may be needed even if the final process is direct compression.

When should a manufacturer use co-processed excipients?

Co-processed excipients can improve flow, compaction, and robustness when a standard microcrystalline cellulose-calcium phosphate system produces unacceptable variation. They may be useful when:

• The active has poor flow.
• The formulation shows capping or lamination.
• Tablet weight is constrained.
• Compression speed must increase.
• The manufacturer wants to reduce the number of individual excipient additions.

The commercial tradeoff is regulatory and supply complexity. A co-processed excipient can require more extensive characterization, a narrower supplier base, and additional comparability work. It should not be used solely to differentiate a generic product unless it provides a measurable manufacturing or stability benefit.

What formulation attributes are commercially important for sitagliptin?

The most valuable formulation attributes are robust dissolution, low moisture sensitivity, high content uniformity, and reliable tablet appearance.

Dissolution performance

Sitagliptin tablets must release the active rapidly and consistently across strengths. The lubricant level and blending time require control because excess hydrophobic lubricant can reduce wetting and slow dissolution.

Critical development variables include:

• Lubricant concentration.
• Lubrication time.
• Active-particle size.
• Disintegrant grade and incorporation method.
• Compression force.
• Tablet porosity.
• Film-coat weight gain.

A formulation that achieves rapid dissolution without relying on aggressive disintegrant loading generally offers the most robust scale-up profile.

Moisture and solid-state control

Sitagliptin phosphate monohydrate is a salt hydrate. Water activity, drying conditions, and storage humidity can affect powder behavior, tablet hardness, and stability. The formulation team should characterize:

• Water content.
• Hydrate state.
• Hygroscopicity.
• Solid-state form.
• Blend uniformity after humidity exposure.
• Dissolution after accelerated storage.

Dibasic calcium phosphate can improve powder flow but may alter moisture distribution within the blend. Excipient compatibility studies should evaluate both the active ingredient and the phosphate-containing filler.

Film coating

The coating is a practical differentiation area for generic manufacturers. A conventional polyvinyl alcohol coating can be optimized for:

• Lower coating time.
• Reduced solvent or water consumption.
• Better color uniformity.
• Improved resistance to chipping.
• More efficient visual strength identification.
• Lower coating cost per batch.

A transparent or lightly colored coat may reduce pigment cost, but tablet appearance must remain sufficiently distinct across the 25 mg, 50 mg, and 100 mg strengths to reduce dispensing errors.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a single proprietary excipient. It is a validated formulation platform that supports consistent manufacturing across all sitagliptin strengths.

Direct-compression excipient systems

Suppliers can offer prequalified systems based on:

• Microcrystalline cellulose and dibasic calcium phosphate.
• High-functionality fillers with improved flow.
• Low-moisture grades.
• Lubricant-compatible compaction systems.
• Co-processed filler-disintegrant combinations.

The value proposition should be quantitative. Suppliers should demonstrate improved tensile strength, ejection force, dissolution, blend uniformity, or press throughput against standard grades.

Film-coating systems

Film-coating suppliers can target generic sitagliptin manufacturers with:

• Ready-to-use polyvinyl alcohol systems.
• Low-weight-gain coatings.
• Rapid-dispersing coating suspensions.
• Titanium-dioxide-reduced systems where permitted.
• Color systems that map clearly to the three commercial strengths.

Coating suppliers can gain share by reducing process time and minimizing tablet rejects rather than by changing the core formulation.

Lubricant systems

Lubrication is a smaller but technically important opportunity. Sodium stearyl fumarate may be attractive where a manufacturer wants lower sensitivity to over-lubrication or improved tablet disintegration. Magnesium stearate remains the lower-cost benchmark.

A supplier claiming a performance advantage should support it with data on:

• Ejection force.
• Tablet tensile strength.
• Disintegration time.
• Dissolution profile.
• Blend uniformity.
• Stability after accelerated storage.

How does Januvia compare with Janumet and Janumet XR from an excipient perspective?

Januvia is a single-active sitagliptin tablet. Janumet and Janumet XR combine sitagliptin with metformin, creating more demanding formulation and manufacturing requirements.

Product	Active ingredients	Primary formulation challenge
Januvia	Sitagliptin phosphate monohydrate	Low-dose uniformity, compression, dissolution
Janumet	Sitagliptin phosphate monohydrate and metformin hydrochloride	High-dose metformin loading and dual-active uniformity
Janumet XR	Sitagliptin phosphate monohydrate and extended-release metformin hydrochloride	Controlled release, high drug loading, profile matching

Janumet XR offers a larger excipient opportunity because extended-release metformin requires matrix-forming or release-controlling technology. Depending on the formulation, relevant excipient classes can include hydrophilic polymers, hydrophobic release modifiers, compression aids, and coating systems.

A supplier that can support both immediate-release Januvia generics and Janumet XR development can increase its commercial relevance to generic manufacturers. However, combination-product development has higher bioequivalence and process risk.

What patent and exclusivity issues affect excipient opportunities?

Excipient selection generally does not eliminate infringement risk from active-ingredient, crystalline-form, formulation, or method-of-use patents. A generic manufacturer must assess the full product-specific patent estate.

U.S. regulatory status

Januvia is approved by the FDA as an oral sitagliptin product. FDA approval was based on sitagliptin phosphate monohydrate, and the product is listed as a reference drug in the Orange Book [1,2].

The product’s commercial protection has included:

• Active-ingredient and salt-related patents.
• Patent protection associated with sitagliptin formulations or solid forms.
• Pediatric exclusivity associated with certain listed patents.
• Patent litigation and settlement agreements involving generic applicants.

The principal U.S. compound protection has expired, but later-listed patents and settlement terms have influenced the practical launch date for generic sitagliptin. Generic applicants must review current Orange Book listings, FDA approval status, paragraph IV certifications, and litigation records rather than relying on the original compound-patent expiration date [2,3].

Paragraph IV challenges

Sitagliptin generic applicants can use an abbreviated new drug application with paragraph IV certifications against listed patents. A paragraph IV filing can trigger patent litigation within the statutory period and may create a 30-month stay of approval, subject to the litigation record and court decisions.

The commercial questions are:

• Which listed patents were challenged?
• Whether the generic applicant received first-filer status.
• Whether litigation was dismissed, settled, or adjudicated.
• Whether the settlement permits an earlier launch.
• Whether the settlement covers Januvia alone or also Janumet products.

Excipient changes do not independently avoid a patent directed to the active compound, but they may be relevant to claims directed to a particular formulation, dosage form, or manufacturing process. A freedom-to-operate review should map every proposed excipient system against the claims of active, formulation, process, and combination patents.

When does Januvia lose exclusivity and when can generics launch?

Januvia’s effective generic-entry date depends on the patent and settlement record, not simply on the earliest patent expiration.

Merck has reported that Januvia faces generic competition after the expiration of key U.S. intellectual-property protection. Public company disclosures have associated U.S. generic entry with the mid-2020s, while certain international markets may follow different timelines [3]. The Orange Book and individual settlement agreements are the controlling sources for product-specific timing [2].

A generic launch scenario can be divided into three stages:

Stage	Commercial consequence
Pre-entry development	Formulation, bioequivalence, patent certification, and manufacturing readiness
Settlement-permitted entry	Potential launch before complete resolution of all later patents
Broad market entry	Multiple suppliers, price erosion, tenders, and channel substitution

The first approved or first-launched products may retain a temporary commercial advantage. Later entrants will compete primarily on price, supply reliability, authorized-distributor access, and combination-product coverage.

What generic-entry risks exist for Januvia?

The main risks are price erosion, rapid supplier crowding, and substitution toward other DPP-4 inhibitors or lower-cost diabetes therapies.

Competitive risks

Sitagliptin will compete with:

• Generic sitagliptin tablets.
• Generic sitagliptin-metformin products.
• Other DPP-4 inhibitors, including linagliptin, saxagliptin, and alogliptin.
• SGLT2 inhibitors and GLP-1 receptor agonists.
• Low-cost sulfonylureas and metformin-based regimens.

Januvia has a strong physician-recognition advantage, but generic sitagliptin can capture substantial volume after formulary substitution and payer-mandated generic dispensing.

Manufacturing risks

A generic manufacturer’s supply-chain exposure includes:

• Limited sources for qualified sitagliptin active ingredient.
• Variability in active-particle size and bulk density.
• Excipient source changes.
• Coating pigment and colorant qualification.
• Compression-tooling differences.
• Site-transfer comparability.
• Stability failures under tropical or high-humidity conditions.

The most defensible commercial strategy is a dual-source excipient and active-ingredient plan supported by validated alternate suppliers.

What geographic opportunities exist for Januvia excipient and generic development?

The United States, Europe, Japan, China, India, and Latin America have different approval, patent, substitution, and pricing environments.

United States

The U.S. market offers the largest opportunity for standardized generic sitagliptin, but it also has the most visible Orange Book and paragraph IV framework. ANDA applicants require product-specific bioequivalence and manufacturing compliance.

Europe

European opportunities depend on national reimbursement, decentralized or centralized regulatory routes, and patent status by country. Excipient substitutions must comply with the relevant quality and labeling requirements, while launch timing depends on national patent enforcement.

Emerging markets

India, Brazil, Mexico, Southeast Asia, and selected Middle Eastern markets may offer earlier volume opportunities, but pricing is often lower and local registration requirements vary. Manufacturers can compete with:

• Lower-cost excipient systems.
• Localized packaging.
• Smaller batch sizes.
• Regional contract manufacturing.
• Sitagliptin-metformin combinations.

A single global excipient platform is commercially efficient, but regional color, coating, packaging, and supplier changes may be necessary.

How strong is the Januvia patent estate for excipient-based competition?

The patent estate is more significant for the active ingredient, salt, solid form, combinations, and use than for ordinary excipients.

A conventional excipient substitution usually has limited value as a patent-avoidance strategy because:

• Many formulation claims are not limited to one commercial excipient.
• Active-ingredient patents can dominate the product.
• Method-of-use patents can cover diabetes treatment regardless of excipient choice.
• Manufacturing claims may cover process conditions rather than a specific filler or lubricant.

Excipient innovation is more valuable for reducing development cost, improving manufacturability, and differentiating a supplier platform than for creating a standalone market-exclusion position.

What is the revenue exposure from Januvia generic entry?

Merck has disclosed that Januvia and Janumet are major diabetes products within its pharmaceutical portfolio. Generic entry can reduce net sales through:

• Direct unit-price erosion.
• Payer substitution.
• Reduced branded promotion.
• Lower refill retention.
• Switching to combination or competing classes.

The impact will differ by market. U.S. erosion is likely to be faster once multiple generics are available, while branded and tender markets outside the U.S. may show slower or more fragmented substitution. Merck’s annual reports provide the relevant product and franchise sales data [3].

For excipient suppliers, the addressable opportunity is smaller than the drug’s revenue exposure but can remain attractive because generic manufacturers require large, recurring volumes of fillers, disintegrants, lubricants, and coating materials after approval.

Key Takeaways

• Januvia uses a conventional immediate-release tablet platform based on microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, lubricants, and a polyvinyl alcohol film coat.
• The most practical generic strategy is direct compression with a robust, multi-source excipient system.
• The 25 mg strength presents the greatest content-uniformity and segregation risk.
• Film coating, lubricant optimization, and co-processed excipients offer commercial opportunities, but they are manufacturing differentiators rather than strong patent barriers.
• Janumet and Janumet XR create larger technical opportunities because metformin loading and extended-release control increase formulation complexity.
• Generic-entry timing depends on current Orange Book listings, paragraph IV certifications, litigation, and settlement terms.
• The strongest supplier proposition is a validated platform that improves flow, compaction, dissolution, stability, and scale-up across all sitagliptin strengths.
• Patent work must cover active, salt, solid form, formulation, manufacturing, combination, and method-of-use claims.

FAQs

Can a generic Januvia use different excipients?

Yes. An ANDA product can use different inactive ingredients if it meets applicable regulatory requirements, demonstrates bioequivalence, and satisfies quality, stability, labeling, and safety standards.

Is sitagliptin suitable for direct-compression manufacturing?

Yes. The conventional Januvia excipient profile is compatible with a direct-compression development strategy, subject to active-powder flow, content-uniformity, compaction, and dissolution testing.

Which excipient is most important for the 25 mg sitagliptin tablet?

The most important consideration is the complete blending and dilution system, not one excipient in isolation. Microcrystalline cellulose, dibasic calcium phosphate, and the disintegrant system collectively influence uniformity and release.

Are Januvia excipients protected by patents?

Ordinary excipients such as microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and polyvinyl alcohol are not exclusive to Januvia. Specific formulation or process claims may still create infringement issues.

Does Janumet create a larger commercial opportunity than Januvia for excipient suppliers?

Usually. Janumet and especially Janumet XR require more complex control of high-dose metformin, dual-active uniformity, and extended release. That increases the value of high-functionality fillers, matrix polymers, and manufacturing platforms.

References

1. U.S. Food and Drug Administration. (2023). Januvia (sitagliptin) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Merck & Co., Inc.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.